Skip to content

Deep venous thrombosis of the axillary and humeral veins following Ecstasy use: A case report

Khalfy Y. El, Chhaiba Y. Ould, Andaloussi Y. El

World Journal of Advanced Research and Reviews April 30, 2026 DOI: 10.30574/wjarr.2026.30.1.0906 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Case study Case report Peer reviewed
Sample size 1
Population 20-year-old male who consumed ecstasy, diazepam ("Zepam"), and alcohol
Interventions Low-molecular-weight heparin Rivaroxaban hydration analgesics
Duration Follow-up to day 9; compartment syndrome developed on day 7
Measures Venous echodoppler, creatine phosphokinase (CPK)
Topics MDMA
Key findings MDMA use, in this case alongside diazepam and alcohol, was associated with upper-limb deep venous thrombosis, severe rhabdomyolysis (CPK 23,304), and hepatic cytolysis, followed by compartment syndrome on day 7 and persistent nerve deficits despite anticoagulation and supportive care. The authors propose that MDMA-related thrombosis may be linked to the inflammatory response and extensive muscle damage of rhabdomyolysis, and conclude that MDMA can cause lasting multi-organ harm with a potentially poor prognosis.

Abstract

Background: 3,4-methylenedioxymethamphetamine (MDMA), or "Ecstasy," is a semi-synthetic stimulant and hallucinogen widely used recreationally. While known for producing euphoria, it is associated with severe medical complications including serotonin syndrome, rhabdomyolysis, and multi-organ failure. Although MDMA is known to cause various vascular and muscular lesions, deep venous thrombosis (DVT) in the upper limbs remains a rare but serious consequence. Case Presentation: A 20-year-old male was admitted to the emergency department after consuming ecstasy, Zepam, and alcohol. He presented with classic signs of serotonin syndrome (disturbed consciousness, hyperhidrosis, tremors, and fever) alongside intense pain and significant edema in the left upper limb. Diagnostics: Venous echodoppler confirmed thrombosis of the left humeral and axillary veins. Laboratory tests revealed severe rhabdomyolysis (CPK: 23,304) and hepatic cytolysis. Management: Treatment included anticoagulant therapy (low-molecular-weight heparin transitioned to Rivaroxaban), hydration, and analgesics. Complications: On day 7, the patient developed compartment syndrome due to worsening edema. While the edema eventually regressed by day 9, the patient suffered persistent sensitivomotor deficits across the median, ulnar, radial, and musculocutaneous nerves.

Discussion: The relationship between MDMA use and thrombosis may be linked to the inflammatory response and extensive muscle damage seen in rhabdomyolysis, similar to the mechanisms observed in inflammatory myopathies. While other sites of MDMA-induced thrombosis (renal and aortic) have been documented, upper limb DVT is less common.

Conclusion: MDMA use can lead to life-altering, multi-visceral damage. Despite multidisciplinary management, the prognosis for such cases can be poor due to lasting nerve damage and muscle atrophy resulting from vascular and compartment complications.